A recent study by Charles River Associates reveals inequities in access to treatment for multiple sclerosis (MS) across Europe. A summary of key findings, with a link to the full report, can be found at the link below.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.